Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-Pentixafor PET/CT in Lymphoproliferative Diseases
NCT04504526Phase 1Recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Aug 2020
- Primary completion
- Dec 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pentixafor in lymphoma, multiple myeloma (MM) and leukemia, sponsored by The First Hospital of Fujian Medical University. Primary endpoints: Maximum Standardized Uptake Value at 3 years and Overall Survival at 3 years. Started Aug 2020; status: recruiting.
02
Drugs
pentixafor
03
Conditions
lymphomamultiple myeloma (MM)leukemia
Beyond the preview
Go deeper on NCT04504526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504526.